Variables All
Value
Females /males, n (TDM samples) 130 (272) / 185 (399)
Age, years, mean (95%CI)a 24.9 (23.3, 26.4)
Prop. of samples with sampling time, n (n patients) 232 (148)
Sampling time, hours, mean (95%CI)a 5.4 (5.2, 5.6)
Prop. of samples with dose, n (n patients) 587 (274)
Dose, mg, mean (95%CI)a 53.4 (49.7, 57.2)
Prop. of undetectable serum samples (n patients) 80 (68)
Atomoxetine serum conc., nM, mean (95%CI)a 1385 (1194, 1577)
CYP2D6 genotype subgroups, n UM / NM / IM / PM
4 / 163 / 116 / 32
CYP2C19*2 carriers / non-carriers 109 / 206
aThe means were calculated with linear mixed model with no covariates. TDM, therapeutic drug monitoring; Sampling time, time between last dose and blood sampling; CYP, cytochrome P450; UM, ultra-rapid metabolizers; NM, normal metabolizers; IM, intermediate metabolizers; PM, poor metabolizers; CI, confidence intervals. aThe means were calculated with linear mixed model with no covariates. TDM, therapeutic drug monitoring; Sampling time, time between last dose and blood sampling; CYP, cytochrome P450; UM, ultra-rapid metabolizers; NM, normal metabolizers; IM, intermediate metabolizers; PM, poor metabolizers; CI, confidence intervals.